Table 4.
Death | Recurrence | ||||
---|---|---|---|---|---|
Crude HR | adjusted HR a | Crude HR | adjusted HR b | ||
Beclin-1 | Negative | 1.0 | 1.0 | 1.0 | 1.0 |
Positive | 2.39 (1.09–5.24) | 2.51 (1.05–5.99) | 2.27 (1.09–4.75) | 1.85 (0.85–4.06) | |
ARID1A | Negative | 1.0 | 1.0 | 1.0 | 1.0 |
Positive | 1.59 (0.95–2.66) | 1.95 (1.09–3.47) | 1.71 (1.06–2.78) | 2.08 (1.23–3.51) |
Bold indicates statistical significance, p < 0.05
amodel controlled for age, GGT before surgery, ALP before surgery, CEA before surgery, number of lesions, tumor size, lymphatic metastasis, nerve invasion, involving extrahepatic tissue, mucus, tumor generalization, TNM stage.
b model controlled for GGT before surgery, ALP before surgery, CEA before surgery, number of lesions, tumor size, lymphatic metastasis, involving extrahepatic tissue, necrosis, mucus, TNM stage.